The ABL Pathway Biomarker Consortium is an MJFF-funded initiative to develop and validate assays appropriate for assessing the impact of c-Abl kinase inhibitors (e.g.,nilotinib) in clinical studies for Parkinson’s disease.
Partners
Hilal A. Lashuel, PhD, EPFL-Lausanne, Switzerland
Ted Dawson, Johns Hopkins University, USA
David R Walt, Tufts University, USA